Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clonal hierarchy of main molecular lesions in acute myeloid leukaemia

Z. Herudkova, M. Culen, A. Folta, I. Jeziskova, J. Cerna, T. Loja, N. Tom, J. Smejkal, L. Semerad, D. Dvorakova, J. Mayer, Z. Racil

. 2020 ; 190 (4) : 562-572. [pub] 20191210

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012302

Grantová podpora
MUNI/A/1105/2018 Masarykova Univerzita
Ministerstvo Zdravotnictví Ceské Republiky

Genetic mutations in acute myeloid leukaemia (AML) are assumed to occur in a sequential order; however, the predominant hierarchical roles of specific mutated genes have not been fully described. In this study, we aimed to determine the clonal involvement of the most frequent AML-associated mutations. Using a targeted sequencing panel for 18 genes, we traced changes and relative clonal contribution of mutations in 52 patients. We analysed 35 pairs of diagnosis and relapse samples, 27 pairs of primary samples and corresponding patient-derived xenografts, and 34 pairs of total leukocytes and corresponding isolated primitive cells or blast populations. In both relapse and xenografts, we observed conservation of main leukaemic clones and variability was limited to subclones with late-acquired mutations. AML evolution thus mainly involved modification of subclones while the clonal background remained unchanged. NPM1 mutations were identified as the most probable leukaemia-transformation lesion, remaining conserved in contrast to high variation of accompanying subclonal FLT3 and NRAS mutations. DNMT3A mutations represented the most stable mutations forming a preleukaemic background in most samples. Mutations in genes IDH1/2, TET2, RUNX1, ASXL1 and U2AF1 were detected both as preleukaemic and as subclonal lesions, suggesting a non-specific order of acquisition.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012302
003      
CZ-PrNML
005      
20210714132203.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.16341 $2 doi
035    __
$a (PubMed)31822038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Herudkova, Zdenka $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Clonal hierarchy of main molecular lesions in acute myeloid leukaemia / $c Z. Herudkova, M. Culen, A. Folta, I. Jeziskova, J. Cerna, T. Loja, N. Tom, J. Smejkal, L. Semerad, D. Dvorakova, J. Mayer, Z. Racil
520    9_
$a Genetic mutations in acute myeloid leukaemia (AML) are assumed to occur in a sequential order; however, the predominant hierarchical roles of specific mutated genes have not been fully described. In this study, we aimed to determine the clonal involvement of the most frequent AML-associated mutations. Using a targeted sequencing panel for 18 genes, we traced changes and relative clonal contribution of mutations in 52 patients. We analysed 35 pairs of diagnosis and relapse samples, 27 pairs of primary samples and corresponding patient-derived xenografts, and 34 pairs of total leukocytes and corresponding isolated primitive cells or blast populations. In both relapse and xenografts, we observed conservation of main leukaemic clones and variability was limited to subclones with late-acquired mutations. AML evolution thus mainly involved modification of subclones while the clonal background remained unchanged. NPM1 mutations were identified as the most probable leukaemia-transformation lesion, remaining conserved in contrast to high variation of accompanying subclonal FLT3 and NRAS mutations. DNMT3A mutations represented the most stable mutations forming a preleukaemic background in most samples. Mutations in genes IDH1/2, TET2, RUNX1, ASXL1 and U2AF1 were detected both as preleukaemic and as subclonal lesions, suggesting a non-specific order of acquisition.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a klonální evoluce $7 D060965
650    _2
$a buněčné klony $7 D002999
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    12
$a geny nádorové $7 D052138
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a heterografty $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $x terapie $7 D015470
650    _2
$a leukocyty $7 D007962
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední NOD $7 D016688
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    _2
$a transplantace nádorů $7 D009368
650    _2
$a nádorové kmenové buňky $7 D014411
650    _2
$a recidiva $7 D012008
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Culen, Martin $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Folta, Adam $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Jeziskova, Ivana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Cerna, Jana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Loja, Tomas $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Tom, Nikola $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Smejkal, Jiri $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Semerad, Lukas $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Dvorakova, Dana $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Mayer, Jiri $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Racil, Zdenek $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 190, č. 4 (2020), s. 562-572
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31822038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714132202 $b ABA008
999    __
$a ok $b bmc $g 1650632 $s 1132681
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 190 $c 4 $d 562-572 $e 20191210 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a MUNI/A/1105/2018 $p Masarykova Univerzita
GRA    __
$p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...